ArriVent's firmonertinib misses Phase 3 trial goal in lung cancer
ArriVent's Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary progression-free survival endpoint, with independent review showing no meaningful improvement versus chemotherapy.
Story updates
12:40:59 PM UTC
SquawkNews
* Shares of drug developer ArriVent BioPharma fall 62.7% to $10.62 premarket * Co says its experimental drug firmonertinib failed to significantly delay disease worsening or death in a late-stage trial of 398 previously untreated patients with a type of advanced lung cancer linked to a rare genetic mutation * At the higher dose, patients went a median 11 months without their cancer worsening versus 9.5 months on chemotherapy, while tumours shrank in 60% of patients compared with 33% on chemotherapy * Severe side effects occurred in 52% of patients on the higher dose versus 55% on chemotherapy; no new safety concerns were reported * ArriVent is reviewing the full results before deciding the drug's next development steps * As of last close, AVBP up 41.5% YTD (Reporting by Kunal Das in Bengaluru) ((mailto:Kunal.Das2@thomsonreuters.com;)